124 related articles for article (PubMed ID: 24262967)
1. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
Hwang IC; Park JY; Ahn HY; Kim KK; Suh HS; Ko KD; Kim KA
Clin Chim Acta; 2014 Jan; 428():77-81. PubMed ID: 24262967
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.
Kim KA; Song WK; Park JY
Clin Pharmacol Ther; 2009 Nov; 86(5):511-8. PubMed ID: 19693007
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK; Chalabianloo F; Bernard JP; Bramness JG; Molden E; Høiseth G
Ther Drug Monit; 2017 Oct; 39(5):550-555. PubMed ID: 28723731
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
7. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
10. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
11. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
13. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
[TBL] [Abstract][Full Text] [Related]
14. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites.
Bae JW; Jang CG; Lee SY
J Clin Pharmacol; 2011 Dec; 51(12):1704-11. PubMed ID: 21209232
[TBL] [Abstract][Full Text] [Related]
15. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
16. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
17. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
18. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
[TBL] [Abstract][Full Text] [Related]
19. Assessment of CYP450 genetic variability effect on methadone dose and tolerance.
Tsai HJ; Wang SC; Liu SW; Ho IK; Chang YS; Tsai YT; Lin KM; Liu YL
Pharmacogenomics; 2014 May; 15(7):977-86. PubMed ID: 24956251
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
